Adventitious Agent Testing For MMV: How Much Do We Really Know?



01st October 2024 | 10:00am EDT / 7:00am PDT / 3:00pm BST / 4:00pm CEST | Maria Farcet, Head of Cell Culture, Virus Models & Serology in the Global Pathogen Safety / Global Quality team at Takeda and Amina Cherif Louazani, PhD, Viral Safety Manager at PathoQuest |BOOK FREE SEAT FOR THIS WEBINAR

Minute virus of mice (MMV) has contaminated biotechnological processes in the past and specific MMV testing is therefore recommended, if the production cell line is known to be permissive for this virus. Testing is widely done using cell-culture based adventitious virus assays, yet MMV strains may differ in their in vitro cell tropism. Here, I present growth characteristics of different MMV strains on A9 and 324K cells and identified significant differences in susceptibility of these widely used indicator cell lines to infection by different strains of MMV, which has implications for MMV detectability during routine testing of biotechnology process harvests [1]. An MMV specific PCR was evaluated as a more encompassing method and was shown as suitable replacement for cell culture-based detection of the different MMV strains, with the additional benefit that detection is more rapid and does also cover other rodent parvoviruses that might contaminate biotechnological processes. Although no MMV contamination event of human-derived cell lines has been reported in the past, biotechnological processes that are based on these also need to consider MMV-specific testing, as we showed e.g. HEK293, a human-derived cell line commonly used in biopharmaceutical manufacturing as susceptible to productive MMV infection.

[1] Farcet et al., Biotechnology & Bioengineering 2024; 121:131-138; DOI: 10.1002/bit.28573

Presented by Maria Farcet, Head of Cell Culture, Virus Models & Serology in the Global Pathogen Safety / Global Quality team at Takeda

Maria Farcet is Head of Cell Culture, Virus Models & Serology in the Global Pathogen Safety / Global Quality team of Takeda in Vienna, Austria. In her 15+ year career in this field she gained profound expertise in virology and virus safety margins of biological medicinal products.  She currently oversees the establishment and operation of virus test systems to enable virus reduction studies, virus testing and virus neutralization assays, under GMP/GLP.

Followed by Amina Cherif Louazani, PhD, Viral Safety Manager at PathoQuest

Amina Cherif Louazani (PharmD, PhD), Viral Safety Manager at PathoQuest, has a strong background in virology and bioinformatics. She holds a PhD in Infectious Diseases from Aix-Marseille University, France, and specializes in NGS data analysis and protocol development for viral transcriptomes. Amina has published several peer-reviewed articles and held various research and clinical roles. At PathoQuest, she leverages her expertise to provide expert reviews of viral safety assessments based on the iDTECT® platform of NGS assays.  

Sponsored by PathoQuest

PathoQuest is a global CRO providing Next Generation Sequencing (NGS)-based Quality Control testing through its iDTECT® assay platform. This platform enables faster, safer and animal free testing for the release of biotherapies to patients. We offer GMP-validated assays for viral safety and genetic characterization of raw materials, cell and gene therapies, monoclonal antibodies and vaccines. Our laboratories in Paris, France, and Wayne, PA, USA, provide global and reliable support to accelerate the availability of biologics. Learn more: https://pathoquest.com/


We will not sell your information to a third party. See our Privacy Policy

Biopharma Webinars